ASP Isotopes Inc

The chart is entrenched in a Stage 4 decline with confirmed lower highs and lower lows, underpinned by a recent Support Failure. Medium-term bias remains firmly bearish, and short-term conditions favor new short entries as price trades below all major EMAs with accelerating downside volume. Focus on selling at rallies into the 9/21EMA or the prior support zone now acting as resistance.

• ↑Revenue surged 480% YoY to $23.8M in 2025, driven by radiopharmacy operations
• ↑Cash, equivalents & marketable securities total $333M as of Sep 30 2025 to fund growth
• ↓Net loss rose to $34.9M YTD in 2025 from $18.7M prior year